Navigation Links
Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
Date:12/12/2011

roRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function opens potential for a novel class of therapeutics and offers a unique approach to treating disease by modulating entire biological pathways. 

About Regulus Therapeutics, Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in more than 5,000 humans. The company works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including fibrosis, hepatitis C, immuno-inflammatory diseases, metabolic diseases and oncology. Regulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics with an initial focus on fibrosis.

For more information, please visit http://www.regulusrx.com. Regulus is also on YouTube at

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
4. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
5. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, announced that Edwards, ... served as an expert panelist at the invitation of ... Health to discuss medical device innovation at its hearing, ... Evidence Development and Communication." "Edwards has five ...
(Date:7/22/2014)... 22, 2014  Jazz Pharmaceuticals plc (Nasdaq: ... 2014 second quarter financial results on Tuesday, August 5, ... management will host a live audio webcast immediately following ... provide a business and financial update and discuss second ... access the live audio webcast via the Investors & ...
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3
... ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of April 6, 2010 . , ...
... ... , ... ... SILVER SPRING, Md. , March 22 FDA is recommending that healthcare practitioners temporarily suspend use of ...
Cached Medicine Technology:Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 2Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 3Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... are obese during pregnancy may be more likely to have ... "We found that, compared with children born from mothers ... during pregnancy had up to 20 to 30 percent higher ... assistant professor of pediatrics at Children,s Hospital of Pittsburgh. ...
(Date:7/22/2014)... (WASHINGTON, July 22, 2014) The American Society of ... Vanderbilt University School of Medicine, and Robert P. Hebbel, ... the 2014 Ernest Beutler Lecture and Prize for their ... disease. , The Ernest Beutler Lecture, named for the ... and physician-scientist for more than 50 years, is a ...
(Date:7/22/2014)... a member of the Clean Plate Club you eat ... not alone! A new Cornell University study shows that ... puts on his or her plate. "If you ... says Brian Wansink Ph.D., author of the forthcoming book, Slim ... Food and Brand Lab. , Wansink and co-author Katherine Abowd ...
(Date:7/22/2014)... Dr. Ross Feldman says women are often in the dark. ... disease, however, data has shown that post-menopausal women are just ... less likely to be adequately diagnosed and treated. New research ... British Journal of Clinical Pharmacology brings to light a ... identify which women are more prone to heart disease. , ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
Breaking Medicine News(10 mins):Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... LONDON, November 11 Extensive research conducted by the,Imperial ... on the Simbionix PROcedure Rehearsal Studio(TM), was awarded a,Magna ... in Lisbon, Portugal. , The ... world,s first patient specific system to enable clinicians to ...
... ... the home or office using methods and products that are government-approved, but that won,t harm ... ... present The Natural Flu Protection Kit, the first product to emerge from the company’s partnership ...
... ... , ... November 11, 2009 -- HEALTHeCAREERS , North America’s premier healthcare Network, is advertising ... the medical industry continues to be one of the few bright spots in the ...
... ... and the Beyond the Box team can assist seniors and their loved ones with the ... ... relocation and design firm, Beyond the Box , is pleased to announce its new ...
... The following statement can be attributed to Steven ... the American Chemistry Council (ACC) regarding the study published ... the Risk of Self-Reported Male Sexual Dysfunction," by D. ... study of occupational exposure to bisphenol A (BPA) among ...
... School of Public Health researchers will present Nov. 11 ... Health Association,s annual meeting in Philadelphia, including a study ... large-scale worksite wellness program. Additional public health ... Does faith affect how Southern African-American women use ...
Cached Medicine News:Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Findings from New Study on Occupational Exposure to BPA of Limited Relevance to Consumers 2Health News:Worksite wellness programs may reduce employee absenteeism 2
Micro suture forceps....
Mini blades....
... M520 OH3 is a smart ... performance available on the market ... stand. The Leica M520 OH3 ... greatest range of movement and ...
Operating microscope with motorized zoom and variable focus up to 405 mm....
Medicine Products: